Related Experiment Video
Updated: Sep 17, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung
Yongfeng Yu1, Fei Yao2, Jin Wang2
1Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241, Huaihai West Road, Shanghai, 200030, China.
Background:
EGFR mutations have been classified into four functional subgroups (Classical-like, P-loop and αC-helical compressing (PACC), T790M-like, and exon 20 loop insertions) based on their influence on EGFR protein structure, as well as response to various types of EGFR-tyrosine kinase inhibitors (TKIs). However, the differences in molecular phenotypes and clinical outcomes for patients carrying these different forms of EGFR mutations are not fully understood. Here we sought to investigate the distribution of different EGFR structural types in Chinese NSCLC patients and the biological characteristics of each subgroup.
Methods:
2992 EGFR mutant NSCLC patients with available next-generation sequencing result were collected for mutation analysis. 118 patients with targeted RNA sequencing data were further analyzed to compare transcriptome differences across mutation subgroups.
Results:
Across the entire cohort, 80.82% of patients were Classical-like, 5.92% were PACC, 10.76% were T790M-like, and 2.51% were Ex20ins. TP53 was the most common co-occurring mutation across the four subgroups, occurring in 60% of the T790M-like subgroup. Interestingly, the Ex20ins group exhibited a notable proportion of genomic alterations related to DNA repair processes. Additionally, both the Ex20ins and T790M subgroups demonstrated higher tumor mutational burden (TMB) scores. Furthermore, for the first time, we observed transcriptomic heterogeneity within these four subgroups. Classical-like group displayed enrichment of immune-related pathways, including PD1 signaling, CD28 family, and TCR signaling. Notably, the L858R group showed significant enrichment in immune activation signatures, including effector memory CD8 T cells, natural killer cells, and MHC I/II. This suggests a potentially robust immune response in that group. In contrast, the T790M-like subgroups showed lower anti-tumor immune signatures but were marked by a significant enrichment in tumor proliferation signatures.
Conclusion:
In this study, we have employed a structure-based classification approach for EGFR mutants to comprehensively characterize the mutational landscape and heterogeneous biological traits at the transcriptional and functional levels in Chinese patients with NSCLC.
Insights
This study classifies EGFR mutations in Chinese NSCLC patients, revealing distinct molecular and immune profiles for each subgroup. Understanding these differences is key for targeted therapies and predicting patient outcomes.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Epidermal Growth Factor Receptor (EGFR) mutations are classified into four functional subgroups based on structural impact and response to EGFR-tyrosine kinase inhibitors (TKIs).
- The molecular phenotypes and clinical outcomes associated with these EGFR mutation subgroups remain incompletely understood.
- This research investigates the distribution and biological characteristics of different EGFR structural types in Chinese non-small cell lung cancer (NSCLC) patients.
Purpose of the Study:
- To analyze the distribution of EGFR structural mutation subgroups in Chinese NSCLC patients.
- To investigate the biological characteristics, including co-occurring mutations and transcriptomic differences, within these EGFR mutation subgroups.
- To provide a comprehensive understanding of the mutational landscape and heterogeneous biological traits at transcriptional and functional levels.
Main Methods:
- Analysis of next-generation sequencing data from 2992 EGFR-mutant NSCLC patients.
- Targeted RNA sequencing data from 118 patients to compare transcriptome differences across mutation subgroups.
- Structure-based classification of EGFR mutations.
Main Results:
- Classical-like mutations comprised 80.82%, PACC 5.92%, T790M-like 10.76%, and Exon 20 insertions (Ex20ins) 2.51% of the cohort.
- TP53 was the most frequent co-occurring mutation (60%) in the T790M-like subgroup. Ex20ins and T790M subgroups showed higher tumor mutational burden (TMB).
- Transcriptomic analysis revealed distinct immune signatures: Classical-like and L858R groups showed enrichment in immune activation pathways, while T790M-like subgroups exhibited lower anti-tumor immunity but higher tumor proliferation signatures.
Conclusions:
- A structure-based classification approach effectively characterizes the EGFR mutational landscape in Chinese NSCLC patients.
- Significant transcriptomic heterogeneity exists across EGFR mutation subgroups, influencing immune response and proliferation.
- These findings highlight distinct biological profiles for different EGFR mutation types, crucial for personalized treatment strategies.
More Related Videos
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
